Irritable Bowel Syndrome (IBS) Treatment Market Size, Share, Impressive Industry Growth, Analysis Report 2028

The global irritable bowel syndrome (IBS) treatment market is projected to exhibit a significant growth, at a CAGR of around 9.5%, during the forecast period. The disturbance in the function of bowel leads to the occurrence of functional gastrointestinal disorder or say IBS. There are few medications available in the market that offers relief to the disorder. Along with the medications, there are several therapies being introduced in the IBS treatment market which are subjected to treat the syndrome. Stem cell therapy is one among those therapies that has been shown a significant relief in the condition of IBS. The increased understanding of the syndrome followed with immunopathology is aiding the development of new targeted treatment solutions for IBS, which includes the use of stem cell treatment, as they have a capability of modulating the immune system.

A full report of Irritable Bowel Syndrome (IBS) Treatment Market is available at: https://www.omrglobal.com/industry-reports/irritable-bowel-syndrome-ibs-treatment-market

The researchers of Copenhagen have reported the success in the IBS treatment in mice, via using its stem cells, to repair certain damage to the colon. The use of stem cell transplants for the treatment of immune systems has found to be successful in treating IBS. At present, there are two types of stem cells that are particularly used in the IBS treatment, namely, allogeneic stem cells and autologous stem cells. Among these two types, the allogeneic stem cells are considered more preferably over autologous stem cells for the IBS treatment. Allogeneic stem cells can be directly injected into the colon or infused through an IV drip.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/irritable-bowel-syndrome-ibs-treatment-market

In April 2019, Children’s Hospital of Fudan University in China offered a stem cell therapy to a newborn baby suffering with IBS. The hospital was successful in stem cell transplant of a baby in 2015, followed to which, the hospital decided to treat eight other children suffering with the same condition. The stem cell transplants were performed with relatively reduced chemotherapy condition, with an aim to lessen the toxicity of the process for the patients. Therefore, such successful stories related with the stem cell therapy in the treatment of IBS is further expected to propel the IBS treatment market growth during the forecast period.

It is expected that the introduction of stem cell therapy in the treatment of irritable bowel syndrome will offer a chance to overturn the condition in patients dealing with mild, moderate or severe pain of IBS. Though, till date, the use of stem cell therapy has not received a wide FDA approval, and more of it is an experimental process. In addition, the use of stem cells in the IBS treatment entirely depends on the physician that have experienced with the use of allogeneic stem cells, through which, the IBS patients can achieve positive health outcomes.

Global IBS treatment Market-Segmentation

By Type

  • IBS-Constipation
  • IBS-Diarrhea
  • IBS-Mixed
  • IBS-Unsubtyped

By Drug Class

  • Eluxadoline
  • Linaclotide
  • Lubiprostone
  • Others (Rifaximin)